Dr. Magdalena Cilella focuses on patent law matters related to molecular/cell biology, pharmaceuticals and biotechnology. Specifically, Magda has assisted clients with preparation and prosecution of patent applications relating to variety of technologies, including diagnostics, proteins, pharmaceuticals and cosmeceuticals, cell-based assays, plants and medical devices.
Magda brings to the firm a strong research background including experiences in neurodegeneration and tauopathies, specializing in intransglutaminase-induced cross-linking in progressive supranuclear palsy and the effects of Echinacea (over-the-counter dietary supplement) on the human immune system.
Recognition
- Student Speaker Representative, Chicago Chapter for Neuroscience Annual Scientific Meeting, Loyola University Chicago, 2001
- Arthur J. Schmitt Dissertation Fellowship for outstanding academic achievements and in recognition of the scholarly promise of the proposed dissertation research, 2000
- Great Lakes Chapter/American Society for Pharmacology and Experimental Therapeutics, 3rd place award (poster presentation), 2000
Affiliations
- Society for Neuroscience
- American Society for Pharmacology and Experimental Therapeutics
- American Association for the Advancement of Science
- Intellectual Property Owners Association
Publications
-
"Transglutaminase-Induced Cross-Linking of Tau Proteins in Progressive Supranuclear Palsy," co-author, J Neuropath Exp Neurol. 59(11), November 2000, pgs 983-9
(November 1, 2003).
Author: Magdalena O. Cilella, Ph.D.
-
"Transglutaminase Enzyme Activity and Expression of Transglutaminase 1 are increased in Progressive Supranuclear Palsy," co-author, J Neuropath Exp Neurol,"62(2), February 2003, pgs 173-84
(February 1, 2003).
Author: Magdalena O. Cilella, Ph.D.